« Musings on the Terri Schiavo case | Main | Media Bias in Terri Schiavo Case at Extreme Levels in AP, Reuters Reports »
March 21, 2005
Prostate Cancer - Ferring's degarelix shows immediate onset of action and sustained activity
Topics: Clinical Pharmacology- Medical News Today
A dosing study with Degarelix, a novel gonadotrophin-releasing hormone (GnRH) receptor blocker, shows optimum efficacy in prostate cancer at
higher doses.
XXth Congress of the European Association of Urologists (EAU), Istanbul, Turkey, March 19, 2005 ¨C The phase II dose-escalating study, presented for the first time today shows promising prospects for the use of Ferring's degarelix in the treatment of prostate cancer.
Based on these encouraging findings, degarelix is moving forward towards phase III clinical trials.
Posted by Hyscience at March 21, 2005 4:25 PM
Articles Related to Clinical Pharmacology:
- Britain tests first Cannabis related medicine for rheumatoid arthritis - Nov 13, 2005
- Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma - May 26, 2005
- Cystatin C May Push Creatinine Off Risk Radar - May 19, 2005
- Cancer Treatment Success Stuns Scientists - May 16, 2005
- Antibody, cancer drug combo shows promise against breast tumors - May 16, 2005
- USC researchers determine mechanism of action of motexafin gadolinium (Xcytrin) - May 02, 2005
- Herceptin® Combined With Chemotherapy Improves Disease-Free Survival for Patients With Early-Stage Breast Cancer - Apr 26, 2005
- Selenium will have critical role in prostate cancer treatment - Fox Chase Cancer Center - Apr 21, 2005
- Traditional Medicine Derivatives Kill Cancer Cells - Apr 20, 2005
- Compound from Chinese medicine shows promise in head and neck cancer, U-M study finds - Apr 19, 2005
